GLP-1 Picks and Shovels
C@strandby
+1.9%
since Sep 29
The idea
I believe GLP-1 drugs will keep reshaping food, retail, and healthcare for a decade, and the steadier money sits in the supply chain behind them, not just the drugmakers themselves. So this holds pens and glass, fill-finish and bioprocessing capacity, distributors moving the volume, and testing gear, anchored by the two big drugmakers so it still works if suppliers get squeezed. No single name dominates, a small cash slice sits ready for dips, and it's built to be held for years, not traded on headlines.
What it owns
- Every GLP-1 dose ships in a sterile pen or cartridge, and the handful of companies making these components have been the production bottleneck. · West Pharmaceutical ServicesIt makes the elastomer stoppers and injector components that every GLP-1 pen requires, capturing value from rising injectable volumes., Becton DickinsonIt has manufacturing scale for pens and prefilled syringes, earning on GLP-1 volume regardless of which drug wins in the market., Stevanato GroupIt makes the glass cartridges and pen systems that drugmakers cannot ship without, benefiting as cartridge capacity expands to meet demand., CorningIts pharmaceutical glass addresses the same shortage of vials and cartridges, capturing value as drugmakers upgrade and expand their glass supply.25%
- The two market leaders in GLP-1 drugs set the pace for the entire supply chain buildout, so holding a slice of them hedges the take against supplier margin pressure. · Eli LillyIt makes one of the two dominant GLP-1 drugs, so its obesity and diabetes franchise keeps growing as demand outpaces supply., Novo NordiskIt makes Ozempic and Wegovy, the other half of the two-company drug market, keeping the take profitable even if suppliers face price pressure., AmgenIt is a credible third entrant in obesity drugs, hedging the take in case GLP-1 adoption spreads beyond the current market leaders.23%
- Drugmakers rent manufacturing capacity and equipment from these companies to turn bulk drug into finished pens, so their order books grow with production volume. · Thermo Fisher ScientificIt rents sterile fill-and-finish lines where bulk drug converts into finished pens, earning as drugmakers outsource production capacity., DanaherIt sells bioprocessing equipment and consumables used to manufacture the drug substance itself, profiting as GLP-1 production scales., RepligenIt makes filtration and purification consumables used in every batch of peptide drug production, earning recurring revenue tied to output volume., AvantorIt supplies raw materials and single-use products that go into every production run, capturing value from rising drug manufacturing volume.20%
- Major distributors move record drug volume from factory to pharmacy and collect a fee on every shipment, regardless of which company makes the drug. · McKessonIt moves unprecedented volume of GLP-1 boxes from factory to pharmacy and collects a fee on each shipment, earning on total prescriptions regardless of drug., CencoraIt is the second major distributor collecting a toll on GLP-1 volume as prescriptions grow across the market., Cardinal HealthIt rounds out the distribution layer supplying pharmacies with record GLP-1 demand, earning on volume moved rather than drug choice.14%
- Every new production line needs analytical instruments to verify batch purity, a quiet toll embedded across the entire manufacturing buildout. · Agilent TechnologiesIt provides analytical instruments for peptide analysis as GLP-1 manufacturing expands, capturing the other half of the quality-check layer., WatersIt sells instruments that quality-check every batch of peptide drug before shipment, profiting as production scales and regulators demand rigorous testing.10%
- Cash8%